Dear Reader,

I hesitated to even send you this.

After what I heard…

After who told me…

On January 7th… just outside Washington, D.C… I sat across from a man whose family has been tied to global power for decades.

Oil deals. Intelligence circles. Government insiders.

He leaned in and told me something that changed everything I thought I knew about the Iran war.

What you’re seeing on the news?

It’s not the real story.

Not even close.

The strikes… the chaos… the escalation…

It’s all part of something much bigger.

A global deal worth trillions.

And the only reason I know this is because of him — an anonymous contact who risked everything to pass this information along.

I verified it. Cross-checked it. Dug deeper.

And what I uncovered is something every American investor needs to see immediately.

Click here to see the full breakdown before it’s too late.

It’s a coordinated move that could reshape the global economy for decades.

But you need to see it for yourself.

Go here now and uncover the real reason behind the Iran war.

Regards,

Addison Wiggin

Founder, Grey Swan Investment Fraternity

Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street

By Thomas Hughes. Article Published: 7/16/2026.

Abbott Laboratories (NYSE: ABT) gave the market what it wanted in its Q2 earnings report, affirming that its acquisition of Exact Sciences was a sound decision. The critical takeaways are that comparable growth remains solid, the Exact Sciences business is gaining traction, and the near-term margin pressure from the acquisition is less severe than expected.

Looking ahead, improving profitability metrics have supported stronger guidance and market sentiment, as well as a robust rebound in the share price.

The share price rebound will be an important factor in the second half of 2026. Abbott’s stock had become overly depressed relative to its historical valuation and capacity for capital returns, signaling a buying opportunity for investors.

The post-release surge not only confirms support at the existing lows but is also backed by MACD and stochastic signals, suggesting that a full reversal may be underway. The market appears to have misjudged the Exact Sciences deal by focusing too heavily on near-term margin pressure and execution risk rather than its long-term commercial impact on revenue, margins and earnings.

Abbott Laboratories’ Q2 Report a Balm for Frayed Investor Nerves

Abbott Laboratories' Q2 report is solid, with reported growth of 13% and organic growth of 4.8%. Strength was underpinned by Exact Sciences and the 42.3% increase in Diagnostic services it brought, along with an 8.4% increase in Established Pharmaceutical Products and a 7.9% increase in Medical Devices. Nutrition, one of the smaller segments, declined by 3.1%. Strength was evident both domestically and internationally.

Margin news was the catalyst. The company’s margins contracted, but less than expected, leaving gross margin, operating income and net income above analysts' forecasts. The critical takeaway is that adjusted earnings per share (EPS) of $1.31 exceeded expectations by 235 basis points, providing sufficient financial strength to reinvest in the business while continuing to return capital to shareholders.

Guidance is another catalyst for trading in the second half of the year. The company maintained its forecast for organic revenue growth but improved its earnings outlook by raising the midpoint and narrowing the range for full-year results. With momentum building and results expected to accelerate in the second half, the guidance is likely conservative, setting the stage for additional catalysts by year’s end.

Abbott’s Capital Return Outlook Improves

Abbott’s capital returns were never in serious danger, but the threat of margin compression and weaker cash flow was sufficient to weigh on sentiment. The takeaway from the Q2 release, however, is that those concerns were misplaced. Capital returns will continue, including the dividend and share buybacks, and buybacks may accelerate.

As it stands, Abbott is a Dividend King with nearly 55 consecutive increases to its credit, a manageable 70% payout ratio and buybacks that offset the impact of annual increases while building shareholder value. As of mid-July, the dividend yield is attractive at a historical high of approximately 2.8%, while Q2 buybacks reduced the share count by 0.45%.

Analysts and Institutional Trends Reveal Optimistic Support for ABT Shares

Analyst trends reflect the dividend’s safety and the deep-value opportunity presented this year. While price targets have moderated, the market overreacted and pushed the stock below the low end of the target range. Price targets suggest a floor near $90, with substantial upside to the consensus target. Valuation metrics suggest the upside could reach triple digits over time.

The likely outcome is that analysts' price targets begin to firm, increasing conviction in the consensus outlook and the potential for a full stock price recovery. Until then, institutional activity suggests that this group is limiting risk in 2026, owning more than 75% of the shares and buying on balance. Buying is broad-based and includes funds, mutual funds, public retirement accounts and private wealth managers.

Abbott’s risks center on legacy issues related to its baby formula business, competition in the MedTech sector and the integration of Exact Sciences. Integration risks now appear limited, given the Q2 release and guidance update, leaving competition and legacy issues as the primary hurdles. Abbott is mitigating competition through pipeline investment, with numerous positive developments reported this quarter. Legacy issues involve baby formula manufacturing processes, regulatory scrutiny and the unresolved legal matters they have created.

This year’s catalysts include the successful integration of Exact Sciences, the revenue and margin boost from Cologuard and the expansion of MedTech wearables. Libre Duo, the world’s first dual glucose/ketone monitoring system, received the EU’s CE Mark, enabling sales throughout the region. Pipeline news also includes advances in two critical cardiovascular devices. What the market gets wrong is that ABT isn’t merely a legacy healthcare company and bond proxy; it is an innovative MedTech company expanding margins while investing in growth.

Take a look at this formerly classified document:

Most people (professionals included) have never heard of it…

But it’s been quietly protecting the value of your savings, your retirement, and every dollar in your wallet for the last 50 years.

Created under Henry Kissinger in 1974…

It had a name only Washington could love: The U.S.–Saudi Arabia Joint Commission on Economic Cooperation.

And this little-known arrangement helped anchor one of the most important financial relationships on earth: Saudi oil… U.S. dollars… And America’s ability to fund its power.

For half a century, it helped tie global oil trade to the U.S. dollar…

Keeping demand for dollars artificially high…

And protecting the purchasing power of every American who ever saved money, owned a home, or built a retirement account.

On June 9, 2024… It ended quietly.

Now, the war in Iran is shining a huge spotlight on its downfall.

What comes next is a complete reset of the dollar system —

One that could hit your money from every direction.

• Stocks crushed 40% to 80% in real terms.
• Real estate cut in half as buyers vanish.
• Inflation grinding at 10% to 15% — month after month, year after year.

Please understand– if you own stocks, bonds, real estate, cash, or a retirement account tied to the U.S. dollar…

You need to read this short presentation now.

It could be the difference between being blindsided by the reset…

And positioning yourself in the tiny group of gold stocks I believe could soar as the dollar system cracks.

Click here now.

Garrett Goggin, CFA, CMT
Lead Analyst and Founder, Golden Portfolio

5 Space Stocks Face a Brutal Correction: Which Ones Are Still Buys?

By Ryan Hasson. Originally Published: 7/28/2026.

The space trade has endured one of the most violent resets of any sector this year. When SpaceX (NASDAQ: SPCX) debuted on the Nasdaq on June 12, the most anticipated IPO in history triggered a double-digit percentage plunge in many space stocks as capital rotated into the new listing. SpaceX itself later joined the wreckage, with SPCX shares down nearly 50% from their mid-June post-IPO peak. The names that rode the pre-IPO euphoria have been repriced mercilessly, with drawdowns across the group ranging from 50% to more than 70%.

That kind of destruction forces a question worth answering honestly: Which of these stocks are genuine opportunities at these levels, and which remain expensive or broken despite their discounts? Notably, some analysts have argued that this is the best time in a generation to buy space and defense stocks. To sort that out, each of the five names below is measured against the same screen: how far it has fallen, what investors are paying per dollar of sales, whether the underlying economics work and what the overall analyst actions signal.

Rocket Lab: The Best Business, Still Priced Like It

Rocket Lab (NASDAQ: RKLB) closed Monday, July 27, down almost 56% from its 52-week high of $151 and nearly 4% lower for the year. Its operational story, however, has barely missed a beat during the decline. The company recently announced a record $266 million contract with the Space Force for hypersonic test launches. The pending $8 billion Iridium acquisition would add recurring services revenue, Neutron remains on track for its debut later this year, and Q2 earnings are expected on Aug. 10.

The complication is that even after losing more than half its value, RKLB still trades at more than 64 times its $601.8 million in annual sales, with a trailing net loss of $198.2 million. Piper Sandler's mid-July Neutral initiation at $83 made exactly this point: Expensive is a description of price versus fundamentals, not price versus the old high.

Heavy insider selling, including large sales from CEO Peter Beck, has not helped sentiment. The broader consensus remains Moderate Buy, with a $110.29 average target. Still, the verdict here requires patience. Rocket Lab is the highest-quality business in the group, and long-term investors buying today are getting a far better price than those who bought in May. They should do so knowing that the valuation still assumes Neutron succeeds and Iridium integrates cleanly.

AST SpaceMobile: Fresh Upgrades Meet the Sector's Most Extreme Valuation

AST SpaceMobile (NASDAQ: ASTS) is down close to 57% from its high of $133.86 and nearly 20% for the year. Interestingly, the same Piper Sandler analyst who flagged Rocket Lab's valuation initiated coverage of AST SpaceMobile at Overweight with a $100 target in mid-July. Two days later, B. Riley upgraded the stock to Buy with an $85 target. The bull case is genuinely exciting: a direct-to-smartphone satellite network with eight to 10 BlueBird satellites already operational and the next batch launching in August, backed by partners including Vodafone and Rakuten.

But the broader analyst picture is more divided than those headlines suggest. The consensus rating is just Hold, with three sell ratings still on the tape and an average target of $86.95. The baseline numbers also demand respect for the risk. ASTS trades at more than 300 times trailing sales of just $70.9 million, with a trailing loss of $341 million, a debt-to-equity ratio of 1.11 and a fresh $1.15 billion convertible-notes offering adding dilution. Skepticism around the company is also elevated, with short sellers holding almost 20% of the float.

The verdict: For aggressive investors who believe the network can scale, the fresh endorsements and August launch cadence make this a legitimate speculative buy. But for anyone who needs current fundamentals to justify a position, it likely does not qualify yet.

Redwire: The Only Name Still Green, and the Cheapest by Far

Redwire (NYSE: RDW) is the outlier on this list in more than one way. The stock is down a punishing 67% from its 52-week high of $26.64, the second-deepest drawdown of the group. Despite that immense decline, however, it remains up more than 13% year to date, making it the only name here still positive in 2026. That odd combination reflects how extreme the spring spike was, not weakness in the underlying story.

On paper, and at first glance, Redwire stands apart. It trades at roughly six times trailing sales, by far the cheapest multiple in the group, and carries a relatively clean balance sheet, with debt-to-equity recently near 0.1. The business is also well diversified, spanning space infrastructure, a growing defense drone franchise anchored by the NATO Penguin Mk3 award and first-mover work in space-based pharmaceutical research.

The analyst picture supports the case: The consensus across 12 analysts is Moderate Buy, with an average target of $15.44, implying close to 75% upside. The company remains deeply unprofitable on a trailing basis, and ongoing insider selling is the honest caveat. The verdict: On a pure risk-reward basis, Redwire screens as one of the most compelling buying opportunities, along with Rocket Lab, for risk-tolerant investors.

Intuitive Machines: The Deepest Drawdown Hides a Margin Problem

Intuitive Machines (NASDAQ: LUNR) has fallen further than anything else on this list, closing at $13.31 on Monday, July 27, more than 72% below its 52-week high and nearly 20% lower for the year. As covered by MarketBeat earlier this year, the lunar franchise has real substance: a sixth NASA CLPS award in a moon-base program worth nearly $600 million across three firms, a record $1.1 billion backlog and trailing annual revenue of $328 million.

But the screen exposes a problem the headlines do not. For Q1 2026, the company posted a quarterly gross margin of roughly 16%, meaning it keeps less than 20 cents of every revenue dollar before overhead. Revenue growth without economic viability is how a stock suffers a 71% drawdown, and it is why the consensus rating remains Hold. Short interest, at nearly 40% of the float, is the highest in the group, and insider selling has been relentless all year, including repeated sales by the co-founder and chairman and multimillion-dollar disposals by the CEO. For LUNR, the initial objective verdict is that it belongs in the “may not be” column until gross margins show durable improvement. Cheap-looking is not the same as cheap.

Voyager Technologies: The Starlab Option, With an Aug. 3 Test

Voyager Technologies (NYSE: VOYG) closed Monday, July 27, essentially flat for the year and down close to 50% from its high of $52.40, the smallest drawdown of the five. The long-term draw is its majority stake in Starlab, the commercial space station positioned to succeed the ISS when it retires in 2030, alongside a newly completed Astrobotic acquisition that brought with it a $298 million NASA contract. The contract cadence has been impressive, with Sandia National Laboratories and an agentic-AI platform award landing this month alone.

The economics, however, look uncomfortably similar to LUNR's. Net margins sit at negative 72%, and the trailing loss of more than $100 million is large relative to just $166 million in annual sales. On paper, Wall Street remains constructive, with a Moderate Buy consensus across 13 analysts and an average target of $43.64. But the most recent signal cut the other way: Morgan Stanley moved the stock to Underweight with a $39 target on July 15, even as Wedbush and BTIG initiated targets of $46 and $55 the prior month. With a beta of 4.13 and roughly 25% of the float sold short, the stock could move violently on its Q2 report, due Aug. 3, the nearest catalyst among these names. The verdict: a watchlist name, not yet a buy. The report will show whether raised 2026 guidance is translating into better economics.

Sorting the Buys From the Rest

Applying a single initial screen across these five stocks yields a useful first-layer pecking order and helps separate real value from value traps. Redwire offers the best combination of valuation, balance sheet and diversification for investors willing to accept the losses still on the books. Rocket Lab is the franchise worth owning for the long haul, provided buyers accept that they could still be paying a slight premium. AST SpaceMobile is a defensible speculation for aggressive investors, and nothing more conservative than that. Voyager needs its upcoming earnings report to make the case. Intuitive Machines, despite the deepest discount, has the weakest economics in the group and the least urgency to own.

The correction created real opportunities, but it did not make everything cheap. With earnings from three of these names landing in the first two weeks of August, the market is about to referee these objective verdicts in real time.